These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37689630)

  • 41. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases.
    Zanini U; Luppi F; Kaur K; Anzani N; Franco G; Ferrara G; Kalluri M; Mura M
    Respirology; 2024 May; 29(5):387-395. PubMed ID: 38320863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.
    Takei R; Brown KK; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Suzuki A; Furukawa T; Fukuoka J; Johkoh T; Goto Y; Kondoh Y
    Respirology; 2022 May; 27(5):333-340. PubMed ID: 35293077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-life prevalence of progressive fibrosing interstitial lung diseases.
    Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
    Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
    Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
    Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
    [No Abstract]   [Full Text] [Related]  

  • 53. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical relevance of rheumatoid factor and anti-citrullinated peptides in fibrotic interstitial lung disease.
    Zheng B; Donohoe K; Hambly N; Johannson KA; Assayag D; Fisher JH; Manganas H; Marcoux V; Khalil N; Kolb M; Ryerson CJ;
    Respirology; 2022 Oct; 27(10):854-862. PubMed ID: 35652240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 56. Lung CCR6
    Tsukuda TK; Ohnishi H; Fujimoto M; Nakatani Y; Takamatsu K; Naka T; Yokoyama A
    Sci Rep; 2022 Nov; 12(1):19577. PubMed ID: 36380088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
    Lassenius MI; Toppila I; Pöntynen N; Kasslin L; Kaunisto J; Kilpeläinen M; Laitinen T
    Eur Clin Respir J; 2020; 7(1):1702618. PubMed ID: 32002175
    [No Abstract]   [Full Text] [Related]  

  • 59. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
    Nawata T; Shirai Y; Suzuki M; Kuwana M
    Rheumatology (Oxford); 2021 Jan; 60(1):250-255. PubMed ID: 32699895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.